World journal of clinical oncology最新文献

{"title":"Is the use of a transanal drainage tube effective in treating anastomotic leakage for mid-low rectal cancer.","authors":"Yu-Kun Cao, Shi-Lai Yang, Zheng-Qiang Wei","doi":"10.5306/wjco.v16.i4.99801","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.99801","url":null,"abstract":"<p><strong>Background: </strong>Anastomotic leakage (AL) is a severe surgical complication for mid-low rectal cancers. The efficacy of transanal drainage tube (TDT) has rarely been reported.</p><p><strong>Aim: </strong>To evaluate the efficacy of TDT after AL.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 68 patients with mid-low rectal cancer who underwent laparoscopic low anterior resection (LAR) and developed ALs. Leakage were identified using imaging studies and digital rectal examinations when local abscesses or systemic infections were present. In each patient, the leakage site was determined using the index finger and a drainage tube was inserted transanally to drain the abscesses and exudates outside the anus. The clinical outcomes of the patients following transanal drainage were analyzed.</p><p><strong>Results: </strong>A total of 43 patients received TDT treatment, while 25 patients did not receive TDT treatment. Among the patients in the TDT group, 9 required reoperation compared to 12 in the non-TDT group. In the TDT group, 76.74% of the patients were able to restore intestinal continuity, whereas only 40% of the patients in the non-TDT group achieved restored intestinal continuity. In the TDT group, 48.48% of patients developed LAR syndrome (LARS), whereas in the non-TDT group, 90% of patients developed LARS. The median drainage time was 7 days, the median postoperative hospital stay was 21 days, the median fasting time was 6.5 days, and the median hospitalization cost was 109205.93 RMB.</p><p><strong>Conclusion: </strong>TDT use lowered reoperation rate but did not increase hospitalization expenses. After ≥ 1 year of follow-up, its use improved intestinal patency rate and reduced the incidence of LARS.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"99801"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic artery aneurysm with double-rupture phenomenon and circulatory collapse following anesthesia induction: A case report.","authors":"Guang-Yan Xu, Ya-Hong Gong, Yi Wang, Xian-Lin Han, Chang Hao, Li Xu","doi":"10.5306/wjco.v16.i4.100957","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.100957","url":null,"abstract":"<p><strong>Background: </strong>Splenic artery aneurysm (SAA) rupture is a rare, life-threatening condition characterized by acute intra-abdominal hemorrhage and hemodynamic instability. Ruptured SAAs may exhibit a biphasic and relatively slow clinical progression, commonly referred to as the \"double-rupture phenomenon\". The reported incidence of the double-rupture phenomenon ranges 12%-21% in patients with ruptured SAAs, potentially due to variations in intra-abdominal pressure. Following anesthesia induction, muscle relaxation can decrease intra-abdominal pressure, potentially triggering the double-rupture phenomenon and leading to circulatory collapse.</p><p><strong>Case summary: </strong>A 61-year-old female presented to the Department of Emergency with upper abdominal pain, abdominal distension, dizziness, and vomiting. Her vital signs were initially stable. Physical examination revealed abdominal tenderness and positive-shifting dullness. Abdominal contrast-enhanced computed tomography revealed cirrhosis, severe portal hypertension, and splenomegaly. Acute rupture was suggested by a hematoma on the upper left side outside the SAA. Surgeons deemed intravascular intervention challenging and open splenectomy inevitable. Circulatory collapse occurred after anesthesia induction, likely due to a double rupture of the SAA. This double-rupture phenomenon may have resulted from an initial rupture of the SAA into the omental bursa, forming a hematoma that exerted a tamponade effect. A second rupture into the peritoneal cavity may have been triggered by decreased intra-abdominal pressure following anesthesia induction. The patient's life was saved through early, coordinated, multidisciplinary team collaboration. Following cardiopulmonary resuscitation and emergency splenectomy, she recovered without significant postoperative bleeding or hypoxic encephalopathy.</p><p><strong>Conclusion: </strong>Anesthesia-induced pressure reduction may trigger a second SAA rupture, causing collapse. Early diagnosis and multidisciplinary teamwork improve outcomes. This is a rare and life-threatening case of SAA rupture, which is of great significance to the medical community for understanding and handling such emergencies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"100957"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulation of huntingtin-associated protein 1 predicts poor prognosis in gastric cancer.","authors":"Xiang-Yang Wang, Fu-Hai Yang, Zhong-Yuan Yuan, Zhong-Jing Wang, Hong-Feng Zhang, Zi-Hui Xu","doi":"10.5306/wjco.v16.i4.102958","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102958","url":null,"abstract":"<p><strong>Background: </strong>Highly expressed in the gastrointestinal mucosa, huntingtin-associated protein 1 (HAP1) is closely associated with tumor development and prognosis.</p><p><strong>Aim: </strong>To investigate the clinical utility of HAP1 expression in gastric cancer (GC).</p><p><strong>Methods: </strong>We randomly selected 124 GC patients had not undergone preoperative radiotherapy or chemotherapy, they were diagnosed at the Central Hospital of Wuhan between May 2013 and October 2018. Immunohistochemistry was used to detect HAP1 expression in paraffin-embedded GC tissues, as well as metastatic lymph nodes. Their clinical data were collected and all participants were follow up for 5 years. Western blotting and quantitative polymerase chain reaction were used to detect HAP1 levels in 20 matched pairs of fresh GC tissues.</p><p><strong>Results: </strong>HAP1 protein and mRNA levels were lower in fresh GC tissues than in normal mucosal tissues (<i>P</i> < 0.001, respectively). Immunohistochemistry also revealed lower HAP1 expression in GC tissues and metastatic lymph nodes than in normal mucosal tissues (<i>P</i> < 0.05). HAP1 expression in GC was closely associated with differentiation, lymph node metastasis, lymph node ratio, remote metastasis, clinical stage, tumor location, and survival time (<i>P</i> < 0.05). Furthermore, HAP1 expression independently predicted GC (<i>P</i> < 0.05) and was more accurate in advanced GC than in early GC (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>HAP1 is an important prognostic biomarker for GC, with low HAP1 expression positively correlating with poor overall survival, especially in advanced clinical stages.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102958"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144043356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of serrated polyposis syndrome from pathophysiology, diagnosis, and management.","authors":"Zong-Yang Li, Tong Li, Hong-Qiao Cai","doi":"10.5306/wjco.v16.i4.103343","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.103343","url":null,"abstract":"<p><p>This editorial discusses Thompson <i>et al</i>'s original article, which is published in the most recent edition of the <i>World Journal of Clinical Oncology</i> and sheds critical light on the intertwined issues of health anxiety and work loss in individuals diagnosed with serrated polyposis syndrome (SPS). SPS is rare, characterized by the development of multiple serrated colorectal polyps. This editorial provides an overview of SPS, including its pathophysiology, clinical presentation, diagnostic criteria, management strategies, and the psychosocial impact. SPS is linked to molecular alterations, which drive carcinogenesis. Colonoscopy and histological analysis are used for diagnosis. Genetic testing is also considered where there is a family history. Quality of life can be greatly impacted by the psychosocial effects of SPS, especially health anxiety. Further understanding of the molecular mechanisms and creating individualized surveillance are required.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"103343"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment radiomic imaging features combined with immunological indicators to predict targeted combination immunotherapy response in advanced hepatocellular carcinoma.","authors":"Xu Zhang, Xu Zhang, Qian-Kun Luo, Qiang Fu, Pan Liu, Chang-Jie Pan, Chuan-Jiang Liu, Hong-Wei Zhang, Tao Qin","doi":"10.5306/wjco.v16.i4.102735","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102735","url":null,"abstract":"<p><strong>Background: </strong>Early symptoms of hepatocellular carcinoma (HCC) are not obvious, and more than 70% of which does not receive radical hepatectomy, when first diagnosed. In recent years, molecular-targeted drugs combined with immunotherapy and other therapeutic methods have provided new treatment options for middle and advanced HCC (aHCC). Predicting the effect of targeted combined immunotherapy has become a hot topic in current research.</p><p><strong>Aim: </strong>To explore the relationship between nodule enhancement in hepatobiliary phase and the efficacy of combined targeted immunotherapy for aHCC.</p><p><strong>Methods: </strong>Data from 56 patients with aHCC for magnetic resonance imaging with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid were retrospectively collected. Signal intensity of intrahepatic nodules was measured, and the hepatobiliary relative enhancement ratio (RER) was calculated. Progression-free survival (PFS) of patients with high and low reinforcement of HCC nodules was compared. The model was validated using receiver operating characteristic curves. Univariate and multivariate logistic regression and Kaplan-Meier analysis were performed to explore factors influencing the efficacy of targeted immunization and PFS.</p><p><strong>Results: </strong>Univariate and multivariate analyses revealed that the RER, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index were significantly associated with the efficacy of tyrosine kinase inhibitors combined with immunotherapy (<i>P</i> < 0.05). The area under the curve of the RER for predicting the efficacy of tyrosine kinase inhibitors combined with anti-programmed death 1 antibody in patients with aHCC was 0.876 (95% confidence interval: 0.781-0.971, <i>P</i> < 0.05), the optimal cutoff value was 0.904, diagnostic sensitivity was 87.5%, and specificity was 79.2%. Kaplan-Meier analysis showed that neutrophil-to-lymphocyte ratio < 5, platelet-to-lymphocyte ratio < 300, prognostic nutritional index < 45, and RER < 0.9 significantly improved PFS.</p><p><strong>Conclusion: </strong>AHCC nodules enhancement in the hepatobiliary stage was significantly correlated with PFS. Imaging information and immunological indicators had high predictive efficacy for targeted combined immunotherapy and were associated with PFS.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102735"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenocarcinoma of the duodenal papilla with synchronous peritoneal metastases-5 years of overall survival: A case report.","authors":"Julio César Núñez, María Teresa Rivera, Mary Ann Stevens","doi":"10.5306/wjco.v16.i4.103651","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.103651","url":null,"abstract":"<p><strong>Background: </strong>Ampullary adenocarcinomas are a rare disease. They can be classified anatomically or according to their histology into intestinal, pancreatobiliary, and mixed subtypes, with different subtypes having distinct prognoses and potential treatments. We report a clinical case of a patient with mixed type adenocarcinoma of the ampulla of Vater, with predominantly intestinal histology, associated with an isolated and synchronous peritoneal carcinomatosis. It is the only case reported in the literature of duodenal ampulla cancer with synchronous peritoneal metastases, with long-term survival.</p><p><strong>Case summary: </strong>A 53-year-old male patient with non-insulin-dependent diabetes presented with acute abdominal pain in the right hypochondrium. Images revealed dilatation of the biliary tract and the duct of Wirsung, without a clear obstructive factor. Upper gastrointestinal endoscopy revealed a tumor in the duodenal papilla. Biopsies confirmed an adenocarcinoma. In the first surgical step, a biliodigestive bypass was performed in association with resection of the carcinomatosis. Peritoneal metastases was found during the intraoperative period. Subsequently, chemotherapy with the folinic acid, fluorouracil, and oxaliplatin regimen was administered based on histology, and a favorable response was achieved. After a multidisciplinary discussion, the Whipple procedure was performed. A delayed biopsy showed disease-free margins. The patient achieved 5 years of overall survival in August 2024, and 4 years of disease-free survival in September 2024.</p><p><strong>Conclusion: </strong>We conclude that an important value of this work is showing individualized treatment for a patient with cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"103651"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation.","authors":"Li Zhang, Jian Yang, Jun-Jie Li, Chi-Yi Chen, Xiao-Dong Wang, Yan Xie, Wen-Tao Jiang","doi":"10.5306/wjco.v16.i4.100729","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.100729","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the third- leading cause of cancer-related deaths worldwide. The multidisciplinary tumor board (MDTB) has been recognized for improving outcomes in cancer management, but its role in patients with HCC undergoing liver transplantation (LT) remains underexplored.</p><p><strong>Aim: </strong>To evaluate the impact of an MDTB on survival outcomes in patients with HCC undergoing LT.</p><p><strong>Methods: </strong>We retrospectively analyzed 393 patients with HCC who underwent LT at our institution from October 2015 to October 2021. Patients were categorized into the MDTB and non-MDTB groups. We compared preoperative and postoperative characteristics, overall survival (OS), and disease-free survival (DFS) between the two groups.</p><p><strong>Results: </strong>Within the University of California, San Francisco (UCSF) criteria, no significant differences in OS and DFS were noted between the MDTB and non-MDTB groups. However, for patients who exceeded the UCSF criteria, the MDTB group exhibited a substantial improvement in both OS and DFS. The 1-year, 3-year, and 5-year OS rates for the MDTB group in this subgroup were 88.68%, 75.29%, and 61.78%, respectively, compared to 83.02%, 64.07%, and 38.25%, respectively in the non-MDTB group. Similarly, DFS rates were 89.47%, 71.35%, and 63.52%, respectively, <i>vs</i> 82.18%, 53.78%, and 34.04%, respectively.</p><p><strong>Conclusion: </strong>The MDTB approach was particularly beneficial for patients with HCC exceeding the UCSF criteria, significantly improving OS and DFS. These findings advocate for integrating MDTB into clinical practice for optimizing the management of high-risk patients with HCC undergoing LT.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"100729"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long non-coding RNA in the regulation of cell death in hepatocellular carcinoma.","authors":"Jiang Wang, Zi-Xuan Liu, Zhi-Hong Huang, Jie Wen, Zhou-Zhou Rao","doi":"10.5306/wjco.v16.i4.104061","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104061","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, accounting for 90% of all cases. Currently, early diagnosis of HCC can be achieved through serum alpha-fetoprotein detection, B-ultrasound, and computed tomography scanning; however, their specificity and sensitivity are suboptimal. Despite significant advancements in HCC biomarker detection, the prognosis for patients with HCC remains unfavorable due to tumor heterogeneity and limited understanding of its pathogenesis. Therefore, it is crucial to explore more sensitive HCC biomarkers for improved diagnosis, monitoring, and management of the disease. Long non-coding RNA (lncRNA) serves as an auxiliary carrier of genetic information and also plays diverse intricate regulatory roles that greatly contribute to genome complexity. Moreover, investigating gene expression regulation networks from the perspective of lncRNA may provide insights into the diagnosis and prognosis of HCC. We searched the PubMed database for literature, comprehensively classified regulated cell death mechanisms and systematically reviewed research progress on lncRNA-mediated cell death pathways in HCC cells. Furthermore, we prospectively summarize its potential implications in diagnosing and treating HCC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104061"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Candida albicans</i> and colorectal cancer: A paradoxical role revealed through metabolite profiling and prognostic modeling.","authors":"Hao-Ling Zhang, Rui Zhao, Di Wang, Siti Nurfatimah Mohd Sapudin, Badrul Hisham Yahaya, Mohammad Syamsul Reza Harun, Zhong-Wen Zhang, Zhi-Jing Song, Yan-Ting Liu, Sandai Doblin, Ping Lu","doi":"10.5306/wjco.v16.i4.104182","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104182","url":null,"abstract":"<p><strong>Background: </strong>Emerging evidence implicates <i>Candida albicans</i> (<i>C. albicans</i>) in human oncogenesis. Notably, studies have supported its involvement in regulating outcomes in colorectal cancer (CRC). This study investigated the paradoxical role of <i>C. albicans</i> in CRC, aiming to determine whether it promotes or suppresses tumor development, with a focus on the mechanistic basis linked to its metabolic profile.</p><p><strong>Aim: </strong>To investigate the dual role of <i>C. albicans</i> in the development and progression of CRC through metabolite profiling and to establish a prognostic model that integrates the microbial and metabolic interactions in CRC, providing insights into potential therapeutic strategies and clinical outcomes.</p><p><strong>Methods: </strong>A prognostic model integrating <i>C. albicans</i> with CRC was developed, incorporating enrichment analysis, immune infiltration profiling, survival analysis, Mendelian randomization, single-cell sequencing, and spatial transcriptomics. The effects of the <i>C. albicans</i> metabolite mixture on CRC cells were subsequently validated <i>in vitro</i>. The primary metabolite composition was characterized using liquid chromatography-mass spectrometry.</p><p><strong>Results: </strong>A prognostic model based on five specific mRNA markers, <i>EHD4</i>, <i>LIME1</i>, <i>GADD45B</i>, <i>TIMP1</i>, and <i>FDFT1</i>, was established. The <i>C. albicans</i> metabolite mixture significantly reduced CRC cell viability. Post-treatment analysis revealed a significant decrease in gene expression in HT29 cells, while the expression levels of <i>TIMP1</i>, <i>EHD4</i>, and <i>GADD45B</i> were significantly elevated in HCT116 cells. Conversely, <i>LIME1</i> expression and that of other CRC cell lines showed reductions. In normal colonic epithelial cells (NCM460), <i>GADD45B</i>, <i>TIMP1</i>, and <i>FDFT1</i> expression levels were significantly increased, while <i>LIME1</i> and <i>EHD4</i> levels were markedly reduced. Following metabolite treatment, the invasive and migratory capabilities of NCM460, HT29, and HCT116 cells were reduced. Quantitative analysis of extracellular ATP post-treatment showed a significant elevation (<i>P</i> < 0.01). The <i>C. albicans</i> metabolite mixture had no effect on reactive oxygen species accumulation in CRC cells but led to a reduction in mitochondrial membrane potential, increased intracellular lipid peroxidation, and induced apoptosis. Metabolomic profiling revealed significant alterations, with 516 metabolites upregulated and 531 downregulated.</p><p><strong>Conclusion: </strong>This study introduced a novel prognostic model for CRC risk assessment. The findings suggested that the <i>C. albicans</i> metabolite mixture exerted an inhibitory effect on CRC initiation.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104182"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of anlotinib and albumin-bound paclitaxel in 2^nd line and above treatment of advanced gastric cancer: A retrospective study.","authors":"Wen-Ming Liu, Yi-Rui Liu, Yi Peng, Jing Tang, Xiao-Bing Li","doi":"10.5306/wjco.v16.i4.102199","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102199","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy combined with anti-angiogenic therapy has become an important strategy for the treatment of advanced gastric cancer (AGC); however, the regimen needs optimization.</p><p><strong>Aim: </strong>To evaluate the efficacy of albumin-bound paclitaxel (nab-ptx) combined with the small molecule vascular endothelial growth factor inhibitor anlotinib in second-line and beyond treatment of AGC.</p><p><strong>Methods: </strong>We collected data from AGC patients at our hospital who experienced disease progression after first-line chemotherapy and received anlotinib combined with nab-ptx. The primary endpoints included overall survival (OS) and progression-free survival (PFS), while the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).</p><p><strong>Results: </strong>Preliminary results indicated that anlotinib combined with nab-ptx can provide significant efficacy in second-line or above treatment for AGC (median PFS = 6.0 months, median OS = 12.0 months), with an ORR of 42% and a DCR of 78%. Further analysis revealed that patients who experienced hypertension, proteinuria, and hand-foot syndrome during treatment had better efficacy compared to those who did not experience these AEs. Mechanistic studies suggest that this regimen likely exerts synergistic anti-tumor effects by activating the immune response through the reduction of regulatory T-cell proportions. Common adverse reactions included bone marrow suppression, peripheral neuropathy, hypertension, proteinuria, and hand-foot syndrome, which were manageable and resolved with appropriate interventions, indicating the promising application of this regimen in second-line or above treatment for AGC.</p><p><strong>Conclusion: </strong>The combination of anlotinib and nab-ptx shows promising efficacy with fewer toxicities in AGC treatment. The regimen holds promise as a second-line treatment of AGC; however, its specific clinical value requires further research.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102199"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}